Myofibroblasts are considered to be the dominant collagen-producing cells in many pathologies, including wound healing, organ fibrosis and cancer [1] [2] [3] . The speculated role for myofibroblasts in organ fibrosis is diverse and dynamic in the progression of disease. In wound healing, the scarring process reverses when repair is accomplished, with myofibroblasts disappearing after resolution of the wound 1 . In the context of organ fibrosis, myofibroblasts persist, and the extracellular matrix continues to accumulate as a result of unabated tissue insult, replacing the functional parenchyma of the organ and contributing to its failure. Despite increased knowledge of the immune mediators of fibrosis, which are currently the only therapeutic targets to manage organ fibrosis in patients, there is no specific treatment option to control fibrosis and preserve organ function. Effective targeting of myofibroblasts in organ fibrosis remains a challenge because of incomplete knowledge regarding their origin and functional contribution.
The origin of resident myofibroblasts during organ development is undisputed because of their presumptive mesodermal origin; however, their origin during fibrosis continues to be a subject of intense debate. In this regard previous studies have suggested a possible role for vascular pericyte-derived myofibroblasts in the pathogenesis of renal fibrosis 4, 5 , although functional data is lacking. These investigations follow earlier studies first published in cancer and developmental-biology literature suggesting that pericytes may give rise to myofibroblasts 2, [6] [7] [8] . Others have proposed roles for the epithelial-to-mesenchymal transition (EMT) [9] [10] [11] [12] , the endothelial-to-mesenchymal transition (EndMT) 13, 14 and bone marrow recruitment 15, 16 in the emergence of fibrosis-associated myofibroblasts. To unequivocally determine the source and function of myofibroblasts in kidney fibrosis, we used multiple genetic mouse models to track, fate map and ablate mesenchymal cells. Our results inform on potential new therapeutic strategies to control fibrosis.
Result
Myofibroblasts derive from resident and bone-marrow sources Using mice in which we could visualize αSMA + cells (αSMA-red fluorescent protein (RFP) mice) and fate mapping of these cells with newly generated mice harboring αSMA promoter-driven cre-loxP-mediated expression of yellow fluorescent protein (αSMA-Cre; R26-stop-YFP mice), we demonstrated that renal fibrosis (after unilateral ureteral obstruction (UUO)) is associated with a significant (P < 0.05) accumulation of αSMA + myofibroblasts in the interstitium of fibrotic kidneys 17 ( Supplementary Fig. 1a) . In healthy kidneys of αSMA-Cre; R26-stop-YFP mice, only a few interstitial cells were visualized (Supplementary Fig. 1a ). Although interstitial myofibroblasts accumulate in fibrosis, their origin remains unknown. To address this issue, we performed several tracking and fate-mapping experiments using new genetic mouse models.
To assess the contribution of resident fibroblasts as compared to bone marrow-derived mesenchymal cells to the total myofibroblast population in kidney fibrosis, we performed bone marrow transplant experiments using αSMA-RFP 17 and wild-type (WT) mice. We confirmed that total-body irradiation associated with bone marrow transplantation before UUO did not affect fibrotic disease progression (Supplementary Fig. 1b ) and confirmed high bone marrow chimerism in sex-mismatched transplants (~96% chimerism; Supplementary Fig. 1c) . We transplanted WT mice with bone marrow from αSMA-RFP donor mice and also performed a reverse transplant (αSMA-RFP mice transplanted with bone marrow from a WT donor) followed by induction of renal fibrosis. Immunolabeling for αSMA + cells (green) and visualization of αSMA-RFP + cells (red) indicated that in the fibrotic kidneys of the transplanted mice, ~35% of the αSMA + myofibroblasts were bone marrow derived, whereas a r t i c l e s 1 0 4 8 VOLUME 19 | NUMBER 8 | AUGUST 2013 nature medicinẽ 65% of the αSMA + cells were derived from the expansion of resident cells or from sources other than bone marrow (Fig. 1a,b) .
Next we evaluated the proliferation status of myofibroblasts in kidney fibrosis. In αSMA-RFP mice with fibrosis, ~50% of the myofibroblasts showed labeling for the proliferation marker Ki67 (Fig. 1c,d) . These results suggest that 50% of the myofibroblasts are recruited without a need for expansion through proliferation. Our bone marrow transplant studies revealed that bone marrow-derived fibroblasts do not label for proliferation markers ( Supplementary  Fig. 1d,e) , suggesting that the recruitment of bone marrow-derived myofibroblasts occurs without proliferation.
Myofibroblasts are functionally important for renal fibrosis
To address the functional importance of myofibroblasts in fibrosis, we generated mice in which viral thymidine kinase was expressed under the control of an αSMA promoter (αSMA-tk mice). This strategy allowed for the specific ablation of proliferating αSMA + cells in fibrosis without an impact on quiescent, nonproliferating cells. We treated αSMA-tk mice and WT littermates with daily intraperitoneal (i.p.) injections of ganciclovir (GCV) after UUO. We euthanized the mice 10 d later and evaluated αSMA + myofibroblasts by immunostaining. Double immunofluorescence for αSMA and Ki67 in the kidneys of αSMA-tk mice treated with GCV revealed that all proliferating myofibroblasts (locally derived) were targeted for ablation, resulting in an ~50% reduction in the number of interstitial myofibroblasts (Fig. 1c,d) . Together with the data from our bone marrow transplant studies ( Fig. 1a and Supplementary Fig. 1d ), these results suggest that out of the 65% total myofibroblasts that are derived from local sources, ~15% emerged without proliferation.
The ratio of proliferating αSMA + cells to nonproliferating cells on day 2, day 5 and day 10 after the induction of kidney fibrosis remained constant (Fig. 1e) , suggesting a linear pattern of myofibroblast accumulation through proliferation of resident αSMA + cells. Immunohistochemistry analyses of normal kidneys revealed αSMA + cells in large vessel walls, probably smooth muscle cells, as well as a small number of interstitial αSMA + cells (Fig. 1f) . Quantitative measurements of the immunohistochemistry staining revealed an ~50% reduction in the number of interstitial αSMA + cells after UUO in αSMA-tk mice treated with GCV compared to control WT mice (Fig. 1f) , which is similar to the results from the immunofluorescence studies (Fig. 1c,d) . Specific ablation of all proliferating myofibroblasts reduced UUO-induced fibrosis, as evidenced by a significant decrease in Masson trichrome staining (MTS) (Fig. 1g) , a decrease in Sirius red staining ( Supplementary  Fig. 2a ) and a decrease in type I collagen staining ( Supplementary  Fig. 2b,c) . All parameters indicated a 50-60% quantitative reduction in kidney fibrosis after the depletion of proliferating αSMA + myofibroblasts. We found similar results in a genetic model of renal disease fibrosis. We crossed the αSMA-tk mice with Col4a3 knockout (Col4a3 −/− ) mice 18 . We observed an onset of renal disease starting Mesenchymal stem cells and myofibroblast recruitment Undifferentiated bone marrow-derived mesenchymal stem cells (MSCs) from αSMA-RFP mice express low levels of αSMA ( Fig. 3a-c ) and have undetectable RFP expression ( Fig. 3a,b) . Transforming growth factor β1 (TGF-β1) is an important cytokine that has been implicated in the activation of myofibroblasts 20 . Although we did not detect expression of the Col1a1 gene in MSCs or MSCs treated with TGF-β1 (data not shown), suggesting that a longer exposure and additional factors are necessary to induce the expression of matrix proteins such as type I collagen in these cells, TGF-β1 treatment did induce a partial myofibroblast phenotype in the MSCs with robust induction of αSMA expression, suggesting that MSCs may give rise to myofibroblasts in renal fibrosis through TGF-β1-dependent differentiation ( Fig. 3a-c) .
To further validate this notion, we crossed the αSMA-Cre mice with mice harboring floxed alleles of the TGF-β type II receptor gene (Tgfbr2 flox/flox mice) 21 . These mice were born at the expected Mendelian ratios with no obvious developmental defects. They were viable and fertile in adulthood and presented no obvious phenotype or altered life span. Tgfbr2-mediated signaling in αSMA + cells thus seems to be nonessential for normal mouse development, or the loss of Tgfbr2 is compensated by other pathways. We isolated MSCs from the bone marrow of these mice and treated them with TGF-β1. Loss of Tgfbr2 prevented the MSCs from sustaining TGF-β1-induced expression of αSMA and a conversion to myofibroblasts when compared to control WT cells (Fig. 3d,e) , further supporting the notion that TGF-β1 may have a role in the differentiation of MSCs into myofibroblasts in kidney fibrosis. Relative interstitial fibrosis (AU) compared to Col4a3 −/− control littermates, we found an ~50% ablation of αSMA + cells, which resulted in an ~50% reduction in fibrosis, in the αSMA-tk mice with knockout of Col4a3 ( Supplementary  Fig. 3a,b) . Despite reduction in fibrosis and the number of αSMA + myofibroblasts in αSMA-tk mice treated with GCV, macrophage infiltration (as measured by F4/80 + and CD11b + cells) remained unchanged when compared to control WT mice ( Supplementary  Fig. 2d,e) . Although we did not evaluate changes in blood pressure, the number of endothelial cells (CD34 + cells) was the same in αSMA-tk mice treated with GCV as compared to GCV-treated WT control mice (Supplementary Fig. 2f ).
We then transplanted sublethally irradiated αSMA-tk mice with bone marrow from donor αSMA-RFP mice and subjected them to UUO. We also performed a reverse bone marrow transplant (αSMA-RFP mice were transplanted with αSMA-tk bone marrow). We administered GCV to both sets of mice to ablate proliferating fibroblasts. In the GCV-treated αSMA-tk mice transplanted with αSMA-RFP bone marrow, we did not detect proliferating αSMA (FITC + ) myofibroblasts, and the total number of αSMA + cells was reduced by half, whereas the number of bone marrow-derived myofibroblasts was unchanged (Fig. 2a) , supporting the notion that recruitment from bone marrow does not require proliferation. Taken together with data from nontransplanted mice, these results indicate that bone marrow-derived myofibroblasts were not ablated in the αSMA-tk mice treated with GCV (Fig. 1c,d) . Reciprocally, in the GCV-treated αSMA-RFP mice transplanted with αSMA-tk bone marrow, the emergence of proliferating αSMA-RFP + myofibroblasts and bone marrow-derived myofibroblasts was unaffected, confirming that accumulation of αSMA + myofibroblasts from the bone marrow does not require proliferation. The quantification of MTS staining indicated a similar reduction of fibrosis in αSMA-tk mice and αSMA-tk mice transplanted with αSMA-RFP bone marrow, whereas the fibrotic index in αSMA-RFP mice transplanted with αSMA-tk bone marrow was similar to that in control WT mice treated with GCV (Fig. 2b,c) . Taken together these results suggest that the expansion of resident cells and the recruitment of bone marrow-derived cells are functional contributors to kidney fibrosis. at 8 weeks of age in these mice 18, 19 Fig. 4a ). Compared to WT control mice with fibrosis, we found an ~56% reduction in the number of myofibroblasts in αSMA-Cre; Tgfbr2 flox/flox mice with fibrosis (Fig. 3f,g ). This decrease was restricted predominantly to the nonproliferating myofibroblasts, with the number of proliferating myofibroblasts remaining largely unchanged (Fig. 3f) . Despite the 56% reduction in myofibroblast numbers in these mice, fibrosis was reduced by only ~29% when compared to control littermates, and tubular atrophy was only mildly reduced in the αSMA-Cre; Tgfbr2 flox/flox mice (Fig. 3g) . F4/80 + and CD11b + macrophage recruitment was significantly reduced in the αSMA-Cre; Tgfbr2 flox/flox mice with fibrosis ( Fig. 3h  and Supplementary Fig. 4b ). These results suggest that deletion of Tgfbr2 in αSMA + cells affects the recruitment of myofibroblasts derived through differentiation specifically. A decrease in macrophage numbers suggests that myofibroblasts that arise through Tgfbr2-mediated differentiation may help recruit these cells in fibrosis.
NG2 + and PDGFR-b + pericytes increase in kidney fibrosis
To address the role of pericytes in kidney fibrosis, we generated mice in which the YFP, Cre recombinase and viral thymidine kinase genes are expressed under the control of the Cspg4 gene promoter (Cspg4 is hereafter referred to as NG2, its more commonly used synonym, and the mice are hereafter referred to as NG2-YFP, NG2-Cre and NG2-tk mice, respectively). NG2 is a cell-surface chondroitin sulfate proteoglycan that has been identified as a marker for vascular pericytes [22] [23] [24] . Similarly, we used mice in which the RFP, Cre recombinase and viral thymidine kinase genes are expressed under the control of the Pdgfrb gene promoter (Pdgfrb-RFP, Pdgfrb-Cre and Pdgfrb-tk mice, respectively), which is another marker used extensively for pericytes [23] [24] [25] [26] [27] [28] [29] [30] . We detected NG2-YFP + and Pdgfrb-RFP + cells in association with CD31 + endothelial cells, suggesting that pericytes are labeled efficiently in NG2-YFP and Pdgfrb-RFP mice (Supplementary Fig. 4c,d) .
YFP visualization showed a significant accumulation of YFP in NG2 + interstitial cells in UUO-induced renal fibrosis, whereas we found very little labeling in the interstitium of the healthy kidneys (Fig. 4a) . The number of interstitial Pdgfrb + cells also significantly increased after UUO-induced fibrosis (Fig. 4b) . We further confirmed the observed interstitial expansion of NG2 + and Pdgfrb + cells in fibrotic kidneys of the transgenic mice using antibody labeling strategies (Fig. 4c,d ).
Pericytes do not contribute to kidney fibrosis
We used an approach similar to that used for the αSMA-tk mice to address the functional role of NG2 + cells in UUO-induced renal fibrosis. We treated NG2-tk mice and WT littermates with daily i.p. injections of GCV after UUO and then euthanized the mice 10 d later. Quantitative analytic measurements of immunolabeled kidney sections revealed an ~55% reduction in the number of interstitial NG2 + cells after UUO in NG2-tk mice compared to WT littermates (Fig. 4c) . We found similar results when we treated Col4a3 knockout mice (Col4a3 −/− ; a genetic mouse model of kidney disease and fibrosis) crossed with NG2-tk mice Fig. 3c,d) .
Similarly, we treated Pdgfrb-tk mice and WT littermates with daily i.p. injection of GCV after UUO and then euthanized the mice 10 d later. Quantitative analytic measurements of immunolabeled kidney sections revealed an ~80% reduction in the number of interstitial Pdgfrb + cells after UUO in Pdgfrb-tk mice compared to WT littermates (Fig. 4d) . We then assessed renal fibrosis using MTS, Sirius red staining, type I collagen immunolabeling and gene expression measurements. All parameters indicated a nonsignificant reduction in fibrosis after depletion of NG2 + or Pdgfrb + cells (Fig. 4e and Supplementary  Figs. 2c and 5a-d) , suggesting that these cells may not contribute to fibrosis. Macrophage infiltration was unchanged in the pericytedepleted fibrotic kidneys (Supplementary Fig. 5e,f) . We next used fate-mapping experiments to address whether αSMA + myofibroblasts emerge from vascular pericytes in renal fibrosis. Immunolabeling of αSMA + cells in NG2-Cre; R26-stop-YFP reporter mice revealed a 3% overlap on average, indicating that the majority of αSMA + cells did not derive from NG2 + cells (Supplementary Fig. 6a,b) . Notably, Pdgfrb immunolabeling revealed an ~35% overlap with NG2-Cre; R26-stop-YFP + cells, indicating that a subset of Pdgfrb + interstitial cells shares a common lineage with NG2 + vascular pericytes (data not shown). A similar strategy using Pdgfrb-Cre; R26-stop-YFP reporter mice and coimmunolabeling with αSMA + cells revealed a 6% overlap on average (Supplementary Fig. 6c,d) . These results suggest that αSMA + cells do not emerge predominantly from Pdgfrb + cells.
To further confirm that our ablation studies specifically deleted αSMA + cells without altering the numbers of NG2 + and Pdgfrb + cells in renal fibrosis, we surveyed fibrotic kidneys of αSMA-tk mice treated with GCV for NG2 + and Pdgfrb + cells. The numbers of both NG2 + and Pdgfrb + cells remained unaltered in the GCV-treated αSMA-tk mice compared to control fibrotic kidneys (Supplementary Fig. 6e,f) , indicating specific targeting of NG2 − αSMA + and Pdgfrb − αSMA + cells. We performed similar experiments using kidneys from NG2-tk and Pdgfrb-tk mice treated with GCV. The number of αSMA + cells remained the same in both NG2-tk and Pdgfrb-tk mice treated with GCV despite significant (P < 0.05) reductions in the numbers of NG2 + and Pdgfrb + cells, respectively (Supplementary Fig. 6g,h ).
eMt and endMt contribution to myofibroblasts
The EMT has been proposed as a source of myofibroblasts in the kidney, although this idea has been disputed 31, 32 . Inhibition of the EMT program improves renal fibrosis 33 . Using compound transgenic mice, we revisited the EMT program as a source of myofibroblasts. We generated mice in which γGT-Cre-driven cre-loxP mediates the expression of YFP (γGT-Cre; R26-stop-YFPmice). In the kidney, γGT expression can be detected in tubular epithelial cells 9, 33 . We then crossed these mice with αSMA-RFP mice to generate γGT-Cre; R26-stop-YFP; αSMA-RFP mice and subjected them to UUO-induced fibrosis. Visualization of the fluorescent signals in these mice indicated that a significant (P < 0.05) number of tubular cells expressed RFP, with an increasing number of double-positive tubules with the progression of fibrosis. However, a very small number of interstitial αSMA + myofibroblasts arose from a fully executed EMT, accounting for ~5% of the total interstitial αSMA + myofibroblasts (Fig. 5a-e) .
We also generated mice to visualize interstitial αSMA + cells derived from the vascular endothelium. We crossed Cdh5-Cre mice with R26-stop-YFP and αSMA-RFP mice to obtain Cdh5-Cre; R26-stop-YFP; αSMA-RFP mice to fate map the contribution of endothelial cells to the accumulation of myofibroblasts (Fig. 5f ). Vessels were YFP + in the healthy kidney (Fig. 5f) . Visual inspection of the fibrotic kidneys subjected to UUO showed that ~10% of the interstitial myofibroblasts colocalized with markers of vessel-associated endothelial cells (YFP) and αSMA-RFP (red) (Fig. 5f,g ). 
DIsCussION
Many investigators have proposed a central role for myofibroblasts in kidney fibrosis, but functional validation has not previously been attempted. Using newly generated genetic mouse models, we demonstrated that myofibroblasts are a functional contributor of type I collagen production and kidney fibrosis. The origin of myofibroblasts has been an intense source of debate in recent years, with diverse ideas having been proposed for their origin. Some studies have disputed the contribution of the EMT in the emergence of myofibroblasts and fibrosis 31 , whereas others favor the idea that vascular pericytes serve as precursors of myofibroblasts in fibrosis 4,5 on the basis of earlier experiments published in cancer and developmental-biology literature that suggested pericytes as a source for putative myofibroblasts 2, [6] [7] [8] 34 . Many recent studies have also proposed a contribution of EndMT in the generation of myofibroblasts 14, 35, 36 . A suggestion that bone marrow contributes to the total myofibroblast population has also been put forward 15, 16 . Because of the presence of such diverse opinions about the origin of myofibroblasts in fibrosis, we performed a comprehensive study to address all possible sources of myofibroblasts in kidney fibrosis. Our results revealed that accumulation of myofibroblasts occurs predominantly from two different sources. One involves local proliferation of resident tissue fibroblasts (~50%), and the other (35%) involves a contribution of bone marrow-derived cells without any evidence of proliferation in the kidney. We show that bone marrow-derived MSCs can differentiate into myofibroblasts under the influence of TGF-β1, and their potential recruitment of bone marrow is dependent on the expression of Tgfbr2. The loss of Tgfbr2 in αSMA + cells led to an ~56% reduction in the accumulation of myofibroblasts but resulted in an only ~29% reduction in fibrosis. Aside from myofibroblasts derived through the proliferation of local resident fibroblasts, all other sources of the myofibroblast accumulation that occurs through differentiation (bone marrow, EMT and EndMT) seemed to be affected by the loss of Tgfbr2. Collectively these results highlight two possibilities. One, bone marrow-derived and EMT-and EndMT-derived myofibroblasts may not contribute to the predominant amount of type I collagen accumulation observed in fibrosis, supporting some previous observations 4, 5 . Two, because the ablation of proliferating myofibroblasts led to a 50% reduction in fibrosis, the possibility that other (nonmyofibroblast) cells that produce type I collagen exist in kidney fibrosis cannot be ruled out. Future experiments will probably shed more light on this matter.
The conversion of local resident fibroblasts into myofibroblasts involves proliferation, whereas the recruitment of bone marrow-derived myofibroblasts is independent of proliferation and instead relies on migration and differentiation. These findings have the immediate implication for the clinic that antiproliferative drugs can only partially affect total myofibroblast accumulation in the fibrotic kidney. This study provides new insight into the contribution of bone marrow to type I collagen-producing and scarforming myofibroblasts. Our Tgfbr2 deletion experiments suggest that preclinical studies targeting TGF-β1 or its receptor(s) may result in suboptimal responses due to the diverse origins and mechanisms of myofibroblast accumulation.
Using a genetic mouse model that specifically tracked, fate mapped and deleted pericytes, we demonstrated that NG2 + pericytes and platelet-derived growth factor receptor-β (PDGFR-β) + pericytes do not contribute to the myofibroblast population in kidney fibrosis. This was also recently noted in a lung fibrosis model 37 . Additionally, we showed that specific deletion of pericytes does not improve kidney fibrosis or alter the recruitment of myofibroblasts. These results oppose those reported in studies by others using the same UUO kidney fibrosis model 4, 5 . There are many possible explanations for this discrepancy. First, the mice used (Coll1a1-GFP and FoxD1 mice) to track pericytes in two of these previous studies 4,5 may not be specific for pericytes 7 . Second, type I collagen is made by many cell types in the context of fibrosis, including epithelial cells, endothelial cells and several types of mesenchymal cells, and thus the use of Coll1a1-GFP mice to track pericytes may have led to confusing results. Third, the use of FoxD1 mice does not substitute for the use of Pdgfrb-and NG2-promoter-driven mice, as Pdgfrb and NG2 are the accepted pericyte markers 7 . Fourth, antibody labeling can be subjective, whereas the use of a mouse model that allowed pericyte fate mapping combined with immunolabeling strategies is more informative. 
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This study confirms previous reports that the EMT program does not lead to the generation of a substantial number of interstitial myofibroblasts in fibrosis 4, 5, 34 . Our fate-mapping experiments showed that although a significant number of tubular epithelial cells gain αSMA expression in fibrosis, only ~5% of myofibroblasts are truly derived through a fully executed EMT. We also confirm that ~10% of myofibroblasts are derived through the EndMT.
In summary, our comprehensive and functional audit of myofibroblast origin in kidney fibrosis reveals that about half of myofibroblasts emerge through proliferation, and the rest are recruited through differentiation. Local fibroblast expansion contributes to ~50% of the myofibroblast pool, whereas ~35% are recruited from the bone marrow. The EndMT contributes to ~10% and the EMT program generates ~5% of interstitial myofibroblasts, and both the EndMT and EMT probably involve TGF-β1-dependent differentiation 11, 12, 14, 38 . Although we derived this information using kidney fibrosis as a model system, we believe that it will serve as an important baseline for future fibrosis studies in other organs. Our findings also inform new therapy targets for kidney fibrosis, which are urgently needed in the clinic.
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Methods and any associated references are available in the online version of the paper.
